Denali Therapeutics (DNLI) Expected to Announce Quarterly Earnings on Tuesday

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $12.75 million for the quarter.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded down $0.84 during mid-day trading on Friday, reaching $20.75. The company had a trading volume of 831,159 shares, compared to its average volume of 956,052. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The stock's 50 day moving average is $21.62 and its 200-day moving average is $24.67. The stock has a market capitalization of $2.99 billion, a PE ratio of -7.52 and a beta of 1.43.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Steve E. Krognes sold 3,339 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares of the company's stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company's stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock worth $973,442 over the last ninety days. Company insiders own 7.90% of the company's stock.

Wall Street Analyst Weigh In

DNLI has been the topic of several research reports. Stifel Nicolaus raised Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. JPMorgan Chase & Co. dropped their price objective on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a report on Tuesday, January 7th. The Goldman Sachs Group reduced their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. William Blair restated an "outperform" rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Finally, Robert W. Baird assumed coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 price objective for the company. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $37.42.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.